New findings presented at the 2025 ASCO Annual Meeting expanded on HRQOL data from the phase 3 CABINET trial.
GEP-NETs
Advertisement
The guideline includes recommendations for the management of carcinoid syndrome and carcinoid heart disease.
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Positive results from the phase 3 CABINET trial led to the treatment’s approval, which showed a median PFS of 13.8 months.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
A new retrospective study has examined the use of 68Ga-DOTATATE PET/CT in all stages of disease.
The combination of EVE/LAN can significantly prolong PFS in patients with well-differentiated grade 1/2 GEP-NETs.
Video Insights
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.